Pall Corporation (PLL) is a global leader in high-tech filtration, separation, and purification. The company, which has recently expanded its portfolio of life sciences solutions through the acquisition of BioSMB, the multicolumn chromatography platform from Tarpon Biosystems.

BioSMB can be used for the purification of injectable therapeutics while reducing water usage by 50%, the space required by 70% and the materials required by 80%, thereby providing a ‘greener’ yet fully disposable and scalable bio-manufacturing solution. Thanks to linking several continuous processing steps, the production cost (of for example monoclonal antibodies) can be reduced by 80%. By increasing the flexibility and lowering the production cost, the BioSMB has the potential to fit single product facilities to multi-product manufacturing facilities.